Regencell Bioscience Replaces Marcum Asia With HTL as Independent Auditor

Regencell Bioscience ( (RGC) ) has issued an announcement.

Regencell Bioscience announced that its board and audit committee dismissed Marcum Asia CPAs LLP as its independent registered public accounting firm, effective April 16, 2026, and appointed HTL International, LLC to audit its consolidated financial statements for the year ending June 30, 2026. Marcum Asia’s prior audit reports for fiscal years 2024 and 2025 contained no adverse or disclaimed opinions and no unresolved disagreements with the company, though they included an explanatory going-concern paragraph and referenced previously disclosed material weaknesses, and Marcum Asia has formally agreed with the company’s description of the circumstances around its dismissal.

The change in auditors, disclosed in an April 17, 2026 filing, signals a transition in Regencell’s external financial oversight without indicating any reported dispute over accounting principles or audit scope. Investors and other stakeholders may view the move in the context of the company’s earlier going-concern warning and internal control weaknesses, but the orderly handover and confirmation from Marcum Asia suggest the shift reflects a strategic change in audit provider rather than a breakdown in auditor-company relations.

More about Regencell Bioscience

Regencell Bioscience Holdings Limited is a Hong Kong-based company listed on Nasdaq under the ticker RGC. It operates in the bioscience sector, focusing on developing and commercializing treatments, with its financial reporting aligned to a fiscal year ending June 30, and is subject to U.S. securities regulation as a foreign private issuer.

Average Trading Volume: 215,456

Technical Sentiment Signal: Buy

Current Market Cap: $14.74B

For detailed information about RGC stock, go to TipRanks’ Stock Analysis page.